InsidersTradesSigma
Follow the ICU MEDICAL INC/DE stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ICU MEDICAL INC/DE has logged 35 reports. Market capitalisation: €4.3bn. The latest transaction was disclosed on 15 May 2026 (Cession). Among the most active insiders: Jain Vivek. The full history is accessible without an account.
35
Insider Decl.
n/a
Thresholds
€737,139
1 ops.
Buy Volume
€1m
5 ops.
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,899 of 29,064 companies
34.3
score / 100
Value35
Quality33
FCF yld1.9%
Earn yld0.0%
EV/EBITDA19.0x
ROE1.4%
Gross mgn37%
Net mgn0.0%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 May 2026
Declarations35 total
2,447 shares@ US$124.080.0067% mcap35.1% of flowCommon StockSEC:0001669639-26-000003:0
1,254 shares0Common StockSEC:0001534342-26-000008:0
1,254 shares0Common StockSEC:0001871884-26-000001:0
2,424 shares@ US$101.060.0053% mcap100.0% of flowCommon StockSEC:0001645866-26-000001:0
30 shares0Common StockSEC:0001410442-22-000003:0
743 shares0Common StockSEC:0001209191-22-029947:0
4,480 shares@ US$170.785555.0% of flowCommon StockSEC:0001073397-22-000001:0
Canonical exit: 10 Aug 2022 (T+90)
750 shares@ US$173.5621.6% of flowCommon StockSEC:0001669639-22-000002:0
433 shares0Common StockSEC:0001645866-22-000001:0
433 shares0Common StockSEC:0001209191-22-028504:0
352 shares0Common StockSEC:0001871884-22-000001:0
129 shares0Common StockSEC:0001209191-22-028501:0
433 shares0Common StockSEC:0001209191-22-028500:0
433 shares0Common StockSEC:0001209191-22-028497:0
1,444 shares0Common StockSEC:0001669639-22-000001:0
1,011 shares0Common StockSEC:0001615192-22-000001:0
1,444 shares0Common StockSEC:0001727477-22-000001:0
1,772 shares0Common StockSEC:0001410442-22-000002:0
1,444 shares0Common StockSEC:0001698998-22-000001:0
722 shares0Common StockSEC:0001804831-22-000001:0
36,000 shares@ US$58.7975.5% of flowCommon StockSEC:0001410442-22-000001:0
164 shares@ US$58.790.3% of flowCommon StockSEC:0001410442-21-000010:0
12,000 shares@ US$58.7924.2% of flowCommon StockSEC:0001410442-21-000008:0
2,157 shares@ US$243.0089.2% of flowCommon StockSEC:0001073398-21-000006:0
2,424 shares@ US$101.06100.0% of flowNon Qualified Stock Options (right to buy)SEC:0001209191-21-056094:0
25 of 35 declarations
关于 ICU MEDICAL INC/DE
ICU Medical, Inc. (股票代码：ICUI) 是一家总部位于美国的医疗技术公司，在美国纳斯达克上市。公司总部位于加利福尼亚州圣克莱门特，成立于1984年，开发、制造和销售用于医院、替代护理场所和家庭护理环境中的输液治疗、血管通路和重症监护产品。([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398423000009/icui-20221231.htm?utm_source=openai)) 从运营角度来看，ICU Medical 最适合被理解为输液和医院耗材及系统的专业供应商。其产品组合包括动态输液泵、注射泵和大容量输液泵、安全软件、专用和非专用输液器、无针输液接头、外周静脉导管、用于危险药物的密闭式转移装置、药房配药系统，以及一系列呼吸、麻醉、监测和温度管理产品。这种广泛的产品线使得该公司与广泛的临床工作流程相关，而非单一产品利基市场。([ir.icumed.com](https://ir.icumed.com/?utm_source=openai)) ICU Medical 的战略定位受到收购和投资组合行动的影响。2022年收购 Smiths Medical 扩大了其平台，并增加了输液和重症监护领域的规模。最近，该公司于2025年4月完成了一项交易，将其输液解决方案业务转入与 Otsuka Pharmaceutical Factory America 的合资企业，这反映了其重塑投资组合并专注于更高价值类别的有意识举动。这一转变对投资者很重要，因为它改变了公司的收入构成和运营重点。([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398425000035/icui-20250930.htm?utm_source=openai)) 在竞争方面，ICU Medical 在输液系统和耗材领域占据公认地位，医院客户重视产品的可靠性、临床安全性和供应连续性。公司受益于一体化产品和已安装的客户群，但它在全球竞争激烈的市场中与更大的多元化医疗技术公司竞争。其差异化在于专业化、耗材的广度以及捆绑设备、软件和面向工作流程解决方案的能力。([ir.icumed.com](https://ir.icumed.com/?utm_source=openai)) 近期发展主要集中在业务的整合后演变、产品线需求趋势以及输液解决方案剥离至合资企业后投资组合的持续重新定位。对于股票投资者而言，ICUI 仍然是一个与医院利用率、整合执行以及管理层优化系统、耗材和重症监护类别组合能力相关的医疗保健工业故事。([ir.icumed.com](https://ir.icumed.com/node/20516/pdf?utm_source=openai))
